deciphera®
a member of ONO PHARMA
MEDICAL AFFAIRS

MOVE

Vimseltinib Registry

Real-World Patient Experience of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Additional information regarding this clinical trial can be found at **clinicaltrials.gov/study/NCT07075471** or scan the QR code below.

For further information, please visit **TGCTregistry.com** or email **medicalinformation@deciphera.com.**

Vimseltinib is a kinase inhibitor approved for adult patients with symptomatic TGCT for which surgical resection will potentially cause worsening functional limitation or severe morbidity. As this study is observational, it will not influence standard medical care or affect treatment decisions for patients.

Intended for US HCPs Only.


deciphera®
a member of ONO PHARMA
MEDICAL AFFAIRS

© 2026 Deciphera Pharmaceuticals LLC. The following are registered trademarks of Deciphera Pharmaceuticals, LLC.: Deciphera and Deciphera logo.

DCPH-M00856v3 06/26

Study Design

Observational study conducted in the United States (US) to better understand real-world use of vimseltinib, treatment patterns and Health-Related Quality of Life (HRQoL) in patients treated with vimseltinib for TGCT



Primary Outcome Measures

- Duration of vimseltinib treatment (baseline up to 12 months)
- Time to discontinuation of vimseltinib (baseline to discontinuation [estimated up to 12 months])

Inclusion Criteria

- Diagnosis of TGCT according to medical records
- Prescribed vimseltinib per the approved label requirements OR the decision to receive vimseltinib has been made but treatment has not yet been initiated
- Has provided informed consent and medical records release

Exclusion Criteria

- Is an active participant in an interventional clinical trial of vimseltinib

Vimseltinib is a kinase inhibitor approved for adult patients with symptomatic TGCT for which surgical resection will potentially cause worsening functional limitation or severe morbidity. As this study is observational, it will not influence standard medical care or affect treatment decisions for patients.